

Date: 21/10/2020

FREEDOM OF INFORMATION REQUEST FOI/015412 – Lung cancer

I am researching the incidence and treatment of Lung cancer. Could you please answer the following two questions for patients treated by your trust?

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

Afatinib
Alectinib
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
Atezolizumab monotherapy
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Durvalumab
Erlotinib
Gefitinib
Gemcitabine
Necitumumab
Nintedanib with Docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab chemo in combination
Pembrolizumab monotherapy
Pemetrexed
Pemetrexed with Carboplatin
Pemetrexed with Cisplatin
Ramucirumab
Vinorelbine and cisplatin/carboplatin

Q2. Could you please provide the total number of patients with any treatment in the last three months for:

Total non-small cell lung cancer (NSCLC)
Squamous non-small cell lung cancer (Sq NSCLC)
non-squamous non-small cell lung cancer (Non-Sq NSCLC)

- Pharmacy does not have a database that can identify drugs and patient disease.

Information regarding individual patient treatment is held in individual patient records and not available from electronic reporting. Individual patient records are exempt from access under FOI exemption Section 40 Personal Information